A global consensus project convened ten leading dermatologists from around the world to develop a new standard for treating hyperpigmentation, addressing a long-standing gap in clinical guidance for doctors globally.
Beiersdorf ingredient Thiamidol was recommended 100% as the first-line dermocosmetic active for facial hyperpigmentation and also in maintenance therapy.
Thiamidol’s efficacy is proven in more than 120 clinical studies involving over 9,000 participants, following 20 years of research and screening of 50,000 compounds.
Hyperpigmentation is one of the most common yet most complex dermatological conditions worldwide. Until now, no globally accepted clinical guidance existed. This has now changed with the results of a global consensus, developed by ten leading dermatologists from around the world. Among its key findings: Thiamidol, Beiersdorf’s patented ingredient, is the only dermocosmetic active recommended with 100% agreement as first-line therapy for facial hyperpigmentation, including moderate to severe cases, and for maintenance treatment, highlighting the efficacy and safety of Thiamidol.
A global standard for hyperpigmentation treatment
The expert panel represented diverse skin phototypes and regions, from Africa to Asia, Europe to the Americas, encompassing approximately 75% of the world‘s population. Their consensus emphasizes photoprotection as a cornerstone of treatment and highlights the urgent need for accessible, effective solutions. In regions where advanced treatments like lasers are not widely available, dermocosmetic options become even more critical.
Over several months, the experts collaborated through virtual sessions, in-person meetings, and scientifically validated surveys to evaluate the latest scientific evidence and clinical practices. The result is a unified, evidence-based treatment algorithm for the most common pigmentary disorders. The goal: reduce clinical variability and improve patient outcomes. The consensus was published in the Journal of the European Academy of Dermatology and Venereology (EADV) – one of the leading professional journals worldwide.
“This is a historical moment for Eucerin. The Global Consensus on the Management of Melanin Hyperpigmentation Disorders is a scientific milestone that validates our long-standing commitment to highly efficient ingredients,” says Burcu Andreae-Nehlsen, President Derma and Health Care at Beiersdorf. “We are proud that Thiamidol is not only featured as a first-line treatment for hyperpigmentation and its maintenance, but also recognized for its accessibility and efficacy across all skin tones and geographies. This consensus further reinforces our mission to deliver inclusive, science-backed skin care solutions that truly change lives.”
Thiamidol: The only dermocosmetic ingredient with 100% expert agreement
Among the key findings, the consensus identified Thiamidol, Beiersdorf’s patented active ingredient, as the only dermocosmetic active recommended as a first-line treatment for hyperpigmentation, including even moderate to severe cases, as well as for maintenance. It is also the only dermocosmetic ingredient to receive 100% agreement among the expert panel for use in severe melasma and is recommended across multiple hyperpigmentation indications such as facial hyperpigmentation, pigmentation of the folds, acne marks.
“With Thiamidol, our Research & Development team has created a breakthrough ingredient that is both highly effective and exceptionally well-tolerated even on sensitive skin,” states Dr. Gitta Neufang, Chief Scientific Officer at Beiersdorf. “This consensus confirms what science showed: Thiamidol works, even in the most challenging clinical cases of hyperpigmentation such as melasma and on all phototypes as demonstrated in more than 120 clinical studies involving over 9,000 participants worldwide. Thiamidol remains the No. 1 dermocosmetic ingredient for reducing hyperpigmentation and achieving an even skin and radiant tone, turning scientific excellence into impactful innovations that touch people’s lives.”
